The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
Open accessAbstract
F amilial hypercholesterolemia (FH) is a common yet underdiagnosed autosomal dominant disorder that affects 1 in 220 individuals globally. FH is characterized by lifelong elevation of low-density lipoprotein cholesterol (LDL-C) and if untreated leads to early-onset atherosclerosis and increased risk of cardiovascular events. Affected men and women who are untreated have a 30% to 50% risk of a fatal or nonfatal cardiac event by ages 50 and 60 years, respectively. The most common causes of FH are pathogenic variants of the LDL receptor (LDL-R) gene, which are responsible for 85% to 90% of genetically confirmed FH. Pathogenic variants of the apolipoprotein (ApoB) gene, resulting in decreased binding of LDL to the LDL-R, or gain-of-function mutations in the gene for proprotein convertase subtilisin/kexin 9 (PCSK9), resulting in increased destruction of LDL-R, are responsible for 5% to 15% and 1% of cases of FH, respectively. Autosomal recessive FH, caused by homozygous mutations in the LDL-R adaptor protein-1, is associated with a mild homozygous FH (HoFH) phenotype and is beyond the scope of this review. With the exception of HoFH, FH is generally a silent disease. HoFH typically presents with pathognomonic physical findings in childhood, including xanthelasmas, tendon xanthomas, and corneal arcus. By contrast, in the Spanish Familial Hypercholesterolemia Cohort study, xanthomas and corneal arcus were present in <15% and 30% of patients with heterozygous FH (HeFH), respectively. However, the prevalence of these findings increases with age in untreated individuals. Elevated total cholesterol (240 mg/dL [6.2 mmol/L]) is found in up to 28.5 million (11.7%) of Americans over the age of 20 years. Coronary artery disease (CAD) and myocardial infarction (MI) are also very common cardiovascular conditions, with more than 1 million Americans estimated to have had an MI in 2018. Individuals with genetically confirmed FH account for only a small percentage of these cardiac events. In the US National Heart Lung and Blood Institute’s Exome Sequencing Project, only 2% of cases of premature MI in men <50 years and women <60 years of age were found to have a genetic defect in the LDL-R. However, as many as 20% of MIs in younger men (<45 years of age) have been attributed to FH. Given the broad range of causes of hypercholesterolemia and early-onset CAD, it is not surprising that FH is not always in the differential diagnosis for healthcare professionals when confronted with a patient presenting with early CAD. This represents a missed opportunity for the screening of family members (cascade screening) and the early initiation of potentially lifesaving therapies. It is crucial to consider the diagnosis of FH in children with LDL-C persistently >160 mg/dL (4.1 mmol/L), adults with LDL-C >190 mg/dL (4.9 mmol/L) (especially if there is a family history of early-onset CAD), and in all patients with early CAD. Given that FH is an autosomal dominant disorder, an individual who is heterozygous for FH has a 50% chance of passing the gene to his or her children. Homozygous individuals who have identical mutations in both alleles, compound heterozygotes who inherited different mutations in both alleles of the same gene, or double heterozygotes who have mutations in 2 different genes, will have offspring who are all obligate heterozygotes, assuming their partner does not have FH. This review will focus on HeFH and aims to highlight the differences between FH, which is present from birth, and hyperlipidemia secondary to suboptimal diet and lifestyle or other causes of acquired hyperlipidemia that develop later in life. Diagnostic tools and potential treatments for individuals with FH will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Heart disease and stroke statistics-2018 update: a report from the american heart association
Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., Chiuve, S. E., Cushman, M., Delling, F. N., Deo, R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000558 · Cited by 7,146
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Khera, A. V., Won, H.-H., Peloso, G. M., Lawson, K. S., Bartz, T. M., Deng, X., van Leeuwen, E. M., Natarajan, P., Emdin, C. A., Bick, A. G., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.520 · Cited by 942
Wiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., Ose, L., Averna, M., Boileau, C., Borén, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv157 · Cited by 891 · cited 2×
“A special flow chart to detect FH in children has been developed and tested by the European Atherosclerosis Society consensus panel.(29)”
BackgroundMethodSafety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807 · cited 1×
“001), with good safety and tolerability.(94) Patients with FH seem to respond similarly to”
BackgroundRaal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61399-4 · Cited by 756 · cited 2×
“The effect of evolocumab was evaluated in two 12-week trials of patients with HeFH: RUTHERFORD(69) and RUTHERFORD 2.(70) In the RUTHERFORD trial, 167 patients were randomly assigned to evolocumab 350 mg, 420 mg, or placebo every 4 weeks (Q4W) for 12 weeks.”
BackgroundMethodGidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000297 · Cited by 723
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 721
20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
Luirink, I. K., Wiegman, A., Kusters, D. M., Hof, M. H., Groothoff, J. W., de Groot, E., Kastelein, J. J. P., & Hutten, B. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816454 · Cited by 654
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Do, R., Stitziel, N. O., Won, H.-H., Jørgensen, A. B., Duga, S., Angelica Merlini, P., Kiezun, A., Farrall, M., Goel, A., Zuk, O., et al. (2015) · Nature · doi:10.1038/nature13917 · Cited by 650
Wiegman, A., Hutten, B. A., de Groot, E., Rodenburg, J., Bakker, H. D., Büller, H. R., Sijbrands, E. J. G., & Kastelein, J. J. P. (2004) · JAMA · doi:10.1001/jama.292.3.331 · Cited by 649
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.001 · Cited by 622
Clinical Genetic Testing for Familial Hypercholesterolemia
Sturm, A. C., Knowles, J. W., Gidding, S. S., Ahmad, Z. S., Ahmed, C. D., Ballantyne, C. M., Baum, S. J., Bourbon, M., Carrié, A., Cuchel, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.044 · Cited by 615
Mechanisms of disease: genetic causes of familial hypercholesterolemia
Soutar, A. K., & Naoumova, R. P. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0836 · Cited by 608
Williams, R. R., Hunt, S. C., Schumacher, M. C., Hegele, R. A., Leppert, M. F., Ludwig, E. H., & Hopkins, P. N. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90155-6 · Cited by 566
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.04.003 · Cited by 545
Self-citationKastelein, J. J. P., Ginsberg, H. N., Langslet, G., Hovingh, G. K., Ceska, R., Dufour, R., Blom, D., Civeira, F., Krempf, M., Lorenzato, C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv370 · Cited by 533
Nissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522
Raal, F., Scott, R., Somaratne, R., Bridges, I., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 508
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands
Umans-Eckenhausen, M. A., Defesche, J. C., Sijbrands, E. J., Scheerder, R. L., & Kastelein, J. J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03587-x · Cited by 489
Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470
Self-citationSantos, R. D., Gidding, S. S., Hegele, R. A., Cuchel, M. A., Barter, P. J., Watts, G. F., Baum, S. J., Catapano, A. L., Chapman, M. J., Defesche, J. C., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30041-9 · Cited by 419
Self-citationEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., & Wiviott, S. D. (2015) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2015.08.004 · Cited by 360
Hopkins, P. N., Toth, P. P., Ballantyne, C. M., & Rader, D. J. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.03.452 · Cited by 351
Pérez de Isla, L., Alonso, R., Mata, N., Fernández-Pérez, C., Muñiz, O., Díaz-Díaz, J. L., Saltijeral, A., Fuentes-Jiménez, F., de Andrés, R., Zambón, D., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024541 · Cited by 342
ANGPTL3 inhibition in homozygous familial hypercholesterolemia
Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323
Mabuchi, H., Koizumi, J., Shimizu, M., Kajinami, K., Miyamoto, S., Ueda, K., & Takegoshi, T. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00692-4 · Cited by 293
Costantine, M. M., Cleary, K., Hebert, M. F., Ahmed, M. S., Brown, L. M., Ren, Z., Easterling, T. R., Haas, D. M., Haneline, L. S., Caritis, S. N., et al. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.038 · Cited by 275
Langsted, A., Kamstrup, P. R., Benn, M., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30042-0 · Cited by 270
Humphries, S. E., Whittall, R. A., Hubbart, C. S., Maplebeck, S., Cooper, J. A., Soutar, A. K., Naoumova, R., Thompson, G. R., Seed, M., Durrington, P. N., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.038356 · Cited by 267
Statins for children with familial hypercholesterolemia
Vuorio, A., Kuoppala, J., Kovanen, P. T., Humphries, S. E., Tonstad, S., Wiegman, A., Drogari, E., & Ramaswami, U. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006401.pub4 · Cited by 265
Diagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
Statins and congenital malformations: cohort study
Bateman, B. T., Hernandez-Diaz, S., Fischer, M. A., Seely, E. W., Ecker, J. L., Franklin, J. M., Desai, R. J., Allen-Coleman, C., Mogun, H., Avorn, J., et al. (2015) · BMJ · doi:10.1136/bmj.h1035 · Cited by 236
deGoma, E. M., Ahmad, Z. S., O’Brien, E. C., Kindt, I., Shrader, P., Newman, C. B., Pokharel, Y., Baum, S. J., Hemphill, L. C., Hudgins, L. C., et al. (2016) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001381 · Cited by 224
Self-citationGinsberg, H. N., Rader, D. J., Raal, F. J., Guyton, J. R., Baccara-Dinet, M. T., Lorenzato, C., Pordy, R., & Stroes, E. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6685-y · Cited by 214
Moriarty, P. M., Parhofer, K. G., Babirak, S. P., Cornier, M.-A., Duell, P. B., Hohenstein, B., Leebmann, J., Ramlow, W., Schettler, V., Simha, V., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw388 · Cited by 197
Self-citationTen-Year Follow-up After Initiation of Statin Therapy in Children With Familial Hypercholesterolemia
Kusters, D. M., Avis, H. J., de Groot, E., Wijburg, F. A., Kastelein, J. J. P., Wiegman, A., & Hutten, B. A. (2014) · JAMA · doi:10.1001/jama.2014.8892 · Cited by 176
Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia
Kusters, D. M., Wiegman, A., Kastelein, J. J. P., & Hutten, B. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.301430 · Cited by 170
Watts, G. F., Gidding, S., Wierzbicki, A. S., Toth, P. P., Alonso, R., Brown, W. V., Bruckert, E., Defesche, J., Lin, K. K., Livingston, M., et al. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.01.002 · Cited by 164
Pravastatin for the Prevention of Preeclampsia in High-Risk Pregnant Women
Costantine, M. M., & Cleary, K. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827d8ad5 · Cited by 161
Family History and Cardiovascular Risk in Familial Hypercholesterolemia
Wiegman, A., Rodenburg, J., de Jongh, S., Defesche, J. C., Bakker, H. D., Kastelein, J. J. P., & Sijbrands, E. J. G. (2003) · Circulation · doi:10.1161/01.cir.0000058166.99182.54 · Cited by 142
Mata, N., Rodrigo Alonso, K., Badimón, L., Padró, T., Fuentes, F. J., Muñiz-Grijalvo, O., Pérez‐Jiménez, F., López‐Miranda, J., Díaz-Díaz, J. L., Vidal, J. I., et al. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-94 · Cited by 140
Futema, M., Plagnol, V., Li, K., Whittall, R., Neil, H. A. W., Seed, M., Bertolini, S., Calandra, S., Descamps, O. S., Graham, C. A., et al. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102405 · Cited by 138
Amundsen, Å. L., Khoury, J., Iversen, P. O., Bergei, C., Ose, L., Tonstad, S., & Retterstøl, K. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.01.002 · Cited by 137
van der Graaf, A., Cuffie-Jackson, C., Vissers, M., Trip, M., Gagné, C., Shi, G., Veltri, E., Avis, H., & Kastelein, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.002 · Cited by 134
Kastelein, J. J. P., Robinson, J. G., Farnier, M., Krempf, M., Langslet, G., Lorenzato, C., Gipe, D. A., & Baccara‐Dinet, M. T. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6523-z · Cited by 114
Inclisiran: a new promising agent in the management of hypercholesterolemia
Kosmas, C. E., Muñoz Estrella, A., Sourlas, A., Silverio, D., Hilario, E., Montan, P. D., & Guzman, E. (2018) · Diseases · doi:10.3390/diseases6030063 · Cited by 99 · cited 1×
“Inclisiran (ALN-PCS) is a long-acting, synthetic small interfering RNA that is directed against PCSK9 messenger RNA to reduce LDL-C levels.(100) In ORION 1, a phase II multicenter, double-blind, placebocontrolled, multiple-ascending-dose trial (NCT02597127), inclisiran was administered as a subcutaneous injection in p…”
BackgroundWatts, G. F., Gidding, S. S., Wierzbicki, A. S., Toth, P. P., Rodrigo Alonso, K., Brown, W. V., Bruckert, É., Defesche, J. C., Lin, K. K., Livingston, M., et al. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487314533218 · Cited by 89
Duell, P. B., Gidding, S. S., Andersen, R. L., Knickelbine, T., Anderson, L., Gianos, E., Shrader, P., Kindt, I., O'Brien, E. C., McCann, D., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.007 · Cited by 89
Self-citationO'Brien, E. C., Roe, M. T., Fraulo, E. S., Peterson, E. D., Ballantyne, C. M., Genest, J. J., Gidding, S. S., Hammond, E., Hemphill, L., Hudgins, L. C., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.12.008 · Cited by 87
Self-citationThe effects of cholestyramine on high density lipoprotein metabolism
Shepherd, J., Packard, C. J., Morgan, H., Third, J. L. H. C., Stewart, J. M., & Lawrie, T. D. V. (1979) · Atherosclerosis · doi:10.1016/0021-9150(79)90036-4 · Cited by 82
Botha, T. C., Pilcher, G. J., Wolmarans, K., Blom, D. J., & Raal, F. J. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.038 · Cited by 70 · cited 3×
“While in general, statins are contraindicated during pregnancy, some experts have recommended their use after organogenesis beginning in the second trimester in the setting of known FH complicated by prevalent ASCVD and in HoFH.(87) These experts cited a large cohort study of 886 996 completed pregnancies, which inclu…”
BackgroundInfluentialPérez‐Calahorra, S., Laclaustra, M., Marco-Benedí, V., Lamíquiz-Moneo, I., Pedro‐Botet, J., Plana, N., Sánchez-Hernández, R. M., Amor, A. J., Almagro, F., Fuentes, F. J., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.003 · Cited by 69
Use of Statins for Dyslipidemia in the Pediatric Population
Eiland, L. S., & Luttrell, P. K. (2010) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-15.3.160 · Cited by 66
Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
Ito, M. K., & Watts, G. F. (2015) · Drugs · doi:10.1007/s40265-015-0466-y · Cited by 62
Farnier, M., Hovingh, G. K., Langslet, G., Dufour, R., Baccara‐Dinet, M. T., Din-Bell, C., Manvelian, G. Z., & Guyton, J. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.036 · Cited by 61
Neil, H. A. W., Huxley, R., Hawkins, M., Durrington, P. N., Betteridge, D. J., & Humphries, S. E. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00233-8 · Cited by 54
Hartgers, M. L., Defesche, J. C., Langslet, G., Hopkins, P. N., Kastelein, J. J. P., Baccara‐Dinet, M. T., Seiz, W., Hamon, S., Banerjee, P., & Stefanutti, C. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.008 · Cited by 53
Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia
Superko, H. R., Greenland, P., Manchester, R. A., Andreadis, N. A., Schectman, G., West, N. H., Hunninghake, D. B., Haskell, W. L., & Probstfield, J. L. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91264-5 · Cited by 51
Nissen, S. E., Dent-Acosta, R. E., Rosenson, R. S., Stroes, E. S. G., Sattar, N. A., Preiss, D., Mancini, G. B. J., Ballantyne, C. M., Catapano, A. L., Gouni‐Berthold, I., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22518 · Cited by 51
Gooding, H. C., Rodday, A. M., Wong, J. B., Gillman, M. W., Lloyd‐Jones, D. M., Leslie, L. K., & de Ferranti, S. D. (2015) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2015.0168 · Cited by 50
Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent
Davidson, M. H., Dicklin, M. R., Maki, K. C., & Kleinpell, R. M. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.11.2663 · Cited by 49
Management of familial hypercholesterolemia during pregnancy: Case series and discussion
Eapen, D. J., Valiani, K., Reddy, S. G., & Sperling, L. S. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.08.005 · Cited by 40
Vuorio, A. F., Watts, G. F., & Kovanen, P. T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.040 · Cited by 39
New Approaches in Detection and Treatment of Familial Hypercholesterolemia
Hartgers, M. L., Ray, K. K., & Hovingh, G. K. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0665-x · Cited by 37
Chou, R., Dana, T., Blazina, I., Daeges, M., Bougatsos, C., Grusing, S., & Jeanne, T. L. (2016) · Europe PMC (PubMed Central) · Cited by 36
Potential Role of Thyroid Receptor β Agonists in the Treatment of Hyperlipidemia
Jakobsson, T., Vedin, L., & Parini, P. (2017) · Drugs · doi:10.1007/s40265-017-0791-4 · Cited by 36
Prediction of cardiovascular risk in patients with familial hypercholesterolaemia
Villa, G., Wong, B. J. O., Kutikova, L., Ray, K. K., Mata, P., & Bruckert, É. (2017) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcx011 · Cited by 36
Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
Julius, U. (2018) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd5020027 · Cited by 36
Moriarty, P. M., & Hemphill, L. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.002 · Cited by 34
Self-citationIbarretxe, D., Rodríguez-Borjabad, C., Feliu, A., Ángel, B. J., Masana, L., & Plana, N. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.039 · Cited by 31
Universal Lipid Screening in 9- to 11-Year-Olds Before and After 2011 Guidelines
Mihalopoulos, N. L., Stipelman, C. H., Hemond, J., Brown, L. L., & Young, P. C. (2017) · Academic Pediatrics · doi:10.1016/j.acap.2017.11.006 · Cited by 30
Detection of familial hypercholesterolemia in patients from a general practice database
Casula, M., Catapano, A. L., Bernardi, L. R., Visconti, M., & Aronica, A. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.07.004 · Cited by 29
Masana, L., Ibarretxe, D., Rodríguez-Borjabad, C., Plana, N., Valdivielso, P., Pedro‐Botet, J., Civeira, F., López‐Miranda, J., Guijarro, C., Mostaza, J. M., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.905 · Cited by 28
Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics
Lee, S. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.1.36 · Cited by 27
Current Treatment of Familial Hypercholesterolaemia
Lambert, C. T., Sandesara, P. B., Isiadinso, I., Góngora, M. C., Eapen, D. J., Bhatia, N. K., Baer, J., & Sperling, L. S. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.2.76 · Cited by 23
Davidson, M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.014 · Cited by 22
What Should Be the Screening Strategy for Familial Hypercholesterolemia?
McCrindle, B. W., & Gidding, S. S. (2016) · New England Journal of Medicine · doi:10.1056/nejme1611081 · Cited by 21
Progress in the care of familial hypercholesterolaemia: 2016
Bell, D. A., & Watts, G. F. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00070 · Cited by 20
Statins for children with familial hypercholesterolemia
Vuorio, A. F., Kuoppala, J., Kovanen, P. T., Humphries, S. E., Strandberg, T. E., Tonstad, S., & Gylling, H. K. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006401 · Cited by 9
Cited by
Evinacumab in Patients with Refractory Hypercholesterolemia
Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031049 · Cited by 302
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
Warden, B. A., Guyton, J. R., Kovacs, A. C., Durham, J. A., Jones, L. K., Dixon, D. L., Jacobson, T. A., & Duell, P. B. (2023) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.09.001 · Cited by 111
Self-citationBallantyne, C. M., Gellis, L., Tardif, J.-C., Banka, P., Navar, A. M., Asprusten, E. A., Scott, R., Stroes, E. S. G., Froman, S., Mendizabal, G., et al. (2026) · JAMA · doi:10.1001/jama.2025.20620 · Cited by 68
Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices
Thongtang, N., Sukmawan, R., Llanes, E. J. B., & Lee, Z.-V. (2022) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2022.101819 · Cited by 61
Metadata
- Authors
- McGowan, M. P., Hosseini Dehkordi, S. H., Moriarty, P. M., & Duell, P. B.
- Venue
- Journal of the American Heart Association
- Published
- 2019-12-17
- Volume
- 8
- Issue
- 24
- Pages
- e013225-e013225
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2995479243
- Cited by
- 271
- References
- 92
- FWCI
- 17.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.